Protalix BioTherapeutics, Inc. Announces Executive Changes
July 22, 2019 at 04:05 pm EDT
Share
Protalix BioTherapeutics, Inc. announced that Yossi Maimon notified the Company of his resignation from his position as the Company's Vice President and Chief Financial Officer to pursue other opportunities. Until his departure, Mr. Maimon will work together with the Company's finance and accounting teams to ensure a smooth transition of the Company's financial and accounting functions, pending the Company's appointment of his successor.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
PROTALIX BIOTHERAPEUTICS, INC. 
